Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $12.0752W HIGH $29.23
Volume
5.75 M
Value Traded
51.16 M
Short % Float
26.97%
+4.98%Week
+0.29%1 Month
+15.34%3 Month
-10.57%6 Month
+117.25%5 Year
+65.87%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
14.03 B
EPS (TTM)
-1.07
P/E Ratio
-
Ent. Value
13.34 B
Total Shares
797.75 M
Float Shares
152.34 M
Insiders
80.90%
Institutions
17.13%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
SMMT Catalyst Timeline
Dated clinical, regulatory and corporate events for Summit Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Summit Therapeutics Inc.
791Total events
10Upcoming
168Tier-1 (high impact)
2011 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Equity OfferingCorporate
AstraZeneca completes $2.0 billion equity investment in Summit Therapeutics
◆Timing GuidancePresentation
Closing of AstraZeneca equity investment expected by end of this week
▲Partnership / LicenseIvonescimabApprovedCorporate
Summit enters clinical trial collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab plus Datroway
multiple solid tumor settings including breast and lung cancersource ↗
▲Partnership / LicenseIvonescimabApprovedCorporate
Summit and AstraZeneca enter clinical collaboration to evaluate ivonescimab with sonesitatug vedotin in GI cancers
gastrointestinal cancerssource ↗
▲Equity OfferingCorporate
AstraZeneca to make $2.0 billion equity investment in Summit via convertible preferred shares
▲Oral PresentationIvonescimabApprovedPresentation
Updated HARMONi overall survival data presented at WCLC 2026
non-small cell lung cancersource ↗
▲Topline ReadoutIvonescimabApprovedClinical Data
Ivonescimab demonstrates statistically significant OS benefit vs pembrolizumab in HARMONi-2
locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expressionsource ↗
▲Primary Endpoint MetIvonescimabApprovedClinical Data
Ivonescimab demonstrates statistically significant overall survival benefit vs pembrolizumab in HARMONi-2
locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expressionsource ↗
▲Topline ReadoutIvonescimabApprovedClinical Data
Updated HARMONi-2 data including OS presented at WCLC 2026
PD-L1-positive advanced NSCLCsource ↗
▲Partnership / LicenseIvonescimabApprovedCorporate
Collaborations announced with sonesitatug vedotin (Sone-Ve) and Datroway (datopotamab deruxtecan) for ivonescimab combinations
solid tumorssource ↗
▲Full ResultsIvonescimabApprovedClinical Data
Updated OS analysis from HARMONi published in The Lancet Oncology
EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancersource ↗
▲PublicationIvonescimabApprovedPresentation
HARMONi Phase III primary analysis results published in The Lancet Oncology
EGFR-mutated non-small cell lung cancersource ↗
▲Topline ReadoutIvonescimabApprovedClinical Data
Positive topline results from HARMONi-GI1 in first-line advanced biliary tract cancer
first-line advanced biliary tract cancersource ↗
▲NMPA NDA ApprovalIvonescimabApprovedEx-US Regulatory
NMPA approves ivonescimab plus chemotherapy for first-line advanced squamous NSCLC in China
first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC)source ↗
▲Supplemental ApprovalIvonescimabApprovedFDA Decision
NMPA approves ivonescimab plus chemotherapy for first-line sq-NSCLC
first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC)source ↗
●Trial InitiationIvonescimabApprovedTrial
Initiation of global Phase II/III HARMONi-GU1 trial of ivonescimab plus enfortumab vedotin in 1L bladder cancer
First-line locally advanced or metastatic urothelial carcinoma (bladder cancer)source ↗
●Quarterly UpdateCorporate
Summit reported Q2 and six months ended June 30, 2026 financial results
▲Full ResultsIvonescimabApprovedClinical Data
Updated OS analysis from HARMONi trial shows positive trend for ivonescimab plus chemo vs chemo alone
non-small cell lung cancersource ↗
▲Topline ReadoutIvonescimabApprovedClinical Data
Summit previously announced HARMONi results
non-small cell lung cancersource ↗
▲Partnership / LicenseRidinilazoleCorporate
Sale of ridinilazole to Biossil, Inc.
C. difficile infectionsource ↗
●Trial InitiationIvonescimabApprovedTrial
US clinical trial site activations for HARMONi-GI3 planned to begin this quarter
colorectal cancersource ↗
▲Topline ReadoutIvonescimabApprovedClinical Data
Updated OS analysis from HARMONi showed consistent OS trend in western and Asian patients
EGFR-mutated locally advanced or metastatic non-squamous NSCLC post-EGFR TKI therapysource ↗
◆Timing GuidanceIvonescimabApprovedPresentation
Initial study under GSK collaboration expected to begin dosing patients later this quarter
Multiple solid tumorssource ↗
▲Partnership / LicenseIvonescimabApprovedCorporate
Summit announced clinical collaboration with Arcus to evaluate ivonescimab plus casdatifan in RCC
Renal cell carcinomasource ↗
●Trial InitiationIvonescimabApprovedTrial
GSK Collaboration Trials with Risvutatug Rezetecan Expected to Start Mid-2026
solid tumors (B7-H3 expressing)source ↗
●Quarterly UpdateCorporate
Summit conference call to discuss ASCO data and ivonescimab updates
▲First Patient DosedIvonescimabApprovedTrial
Initial study with GSK B7-H3 ADC expected to begin dosing patients
multiple solid tumorssource ↗
◆R&D DayPresentation
Summit Therapeutics update conference call after ASCO 2026 Plenary Session
▲Topline ReadoutIvonescimabApprovedClinical Data
Updated overall survival analysis from HARMONi study with data cut-off June 2026
EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancersource ↗
▲Full ResultsIvonescimabApprovedClinical Data
Additional OS analysis with June 2026 data cut-off
EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancersource ↗
▲Topline ReadoutIvonescimabApprovedClinical Data
Ivonescimab plus chemotherapy demonstrated statistically significant OS benefit vs tislelizumab plus chemotherapy in 1L squamous NSCLC
squamous non-small cell lung cancersource ↗
●Oral PresentationIvonescimabApprovedPresentation
Plenary Session presentation at ASCO 2026 Annual Meeting
squamous non-small cell lung cancersource ↗
●PublicationIvonescimabApprovedPresentation
Simultaneous publication of HARMONi-6 results in The Lancet
squamous non-small cell lung cancersource ↗
◆Oral PresentationIvonescimabApprovedPresentation
Ivonescimab Phase II data in mCRC presented at ASCO 2026
first-line metastatic colorectal cancersource ↗
▲Oral PresentationIvonescimabApprovedPresentation
Positive OS data for HARMONi-6 presented at ASCO 2026 Plenary Session
First-line squamous NSCLCsource ↗
▲Primary Endpoint MetIvonescimabApprovedClinical Data
Ivonescimab plus chemotherapy met primary OS endpoint vs tislelizumab plus chemotherapy in HARMONi-6
First-line squamous NSCLCsource ↗
●Quarterly UpdateCorporate
Summit Therapeutics Q1 2026 financial results and operational update
◆Interim AnalysisTrial
Early interim PFS analysis for HARMONi-3 squamous cohort reviewed by IDMC
squamous non-small cell lung cancersource ↗
●Interim AnalysisIvonescimabApprovedTrial
Interim PFS analysis for squamous cohort of HARMONi-3 reviewed by iDMC; study continues as planned
first-line metastatic squamous NSCLCsource ↗
▲Trial InitiationIvonescimabApprovedTrial
ILLUMINE study began enrolling patients
Head and neck squamous cell carcinomasource ↗
▲Enrollment CompleteIvonescimabApprovedTrial
Enrollment completion expected for non-squamous cohort of HARMONi-3
first-line metastatic non-squamous NSCLCsource ↗
◆Topline ReadoutIvonescimabApprovedClinical Data
Interim results of AK112-206 with data cut-off March 31, 2026
first-line metastatic colorectal cancersource ↗
◆Oral PresentationIvonescimabApprovedPresentation
Multiple Ivonescimab data sets from Phase III studies to be featured at ELCC 2026
advanced NSCLCsource ↗
●Poster PresentationIvonescimabApprovedPresentation
Health-Related Quality of Life with Ivonescimab Versus Pembrolizumab for PD-L1 Positive, NSCLC (HARMONi-2): a Randomised, Double-Blind, Phase 3 Study in China
PD-L1 positive NSCLCsource ↗
◆Oral PresentationPresentation
Summit Therapeutics to present at Oppenheimer 37th Annual Healthcare Conference
◆Oral PresentationPresentation
Summit Therapeutics to present at Leerink Partners Global Healthcare Conference 2026
◆Oral PresentationPresentation
Summit Therapeutics to present at TD Cowen 46th Annual Health Care Conference
▲Enrollment CompleteIvonescimabApprovedTrial
HARMONi-3 Squamous Cohort Enrollment Screening Completed
first-line metastatic squamous NSCLCsource ↗
Past FDA Catalysts and PDUFA Decisions
How SMMT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-15 | ivonescimab | Phase III interim results | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C55 / 100
Pipeline Score
$2.2B
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.2x
rNPV / MCap
Top 12%
Mid Cap(rank 80 of 658)
Percentile Rank
Summit Therapeutics Inc. carries a moderate pipeline score (55/100), with $2.6B risk-adjusted pipeline value, led by Ivonescimab in Non-Squamous Non-small Cell Lung Cancer (Phase 3), across $50B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ivonescimab Monoclonal antibodyNCT05382442 | Metastatic Colorectal Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 984 | Aug 12, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every SMMT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DUGGAN ROBERT WDirector, Officer (Co-Chief Executive Officer), 10% Owner | Buy | 3,810,000 573,883,879 held | $13.12 | 06/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SMMT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 2.4 % (-40 %) | 477.70 M | 32.79 M | -9.91% ( -3.60 M) |
SMMT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-23 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SMMT ranks across every disease it competes in
Competitive Position is a premium feature
See how SMMT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSMMT News
SMMTAstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Summit Therapeutics has successfully closed a $2 billion equity investment from AstraZeneca. This funding will aid in the development of ivonescimab, a promising investigational bispecific antibody targeting PD-1 and VEGF. The partnership is expected to bolster Summit's research capabilities and accelerate the drug's progress towards clinical use.
Read more →SMMTSummit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Summit Therapeutics has entered a clinical trial collaboration with Daiichi Sankyo and AstraZeneca to assess ivonescimab, a PD-1/VEGF bispecific antibody. This partnership aims to evaluate the drug in combination with Datroway, a TROP2-directed ADC, across various solid tumors, including breast and lung cancer. The collaboration signifies a strategic move to advance cancer treatment options.
Read more →SMMT▲ +5.9%on this newsshared move
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
Summit Therapeutics has secured a $2 billion strategic equity investment from AstraZeneca, aimed at advancing cancer treatment initiatives. This collaboration will focus on the development of ivonescimab and sonesitatug vedotin. The partnership is expected to significantly enhance Summit's research capabilities and market presence in oncology.
Read more →SMMTHARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
Summit Therapeutics Inc. announced that data from its Phase III HARMONi-GI1 trial will be presented at the ESMO 2026 Congress. The trial evaluates ivonescimab, a novel bispecific antibody, in combination with chemotherapy for advanced biliary tract cancer. This presentation highlights the potential of ivonescimab in first-line treatment settings.
Read more →SMMT▼ -5.5%on this news
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
Summit Therapeutics Inc. presented updated overall survival results from the Phase III HARMONi trial at the WCLC 2026. The data highlights the effectiveness of ivonescimab combined with chemotherapy in both Western and Asian patients. This investigational bispecific antibody shows promise as a first-in-class treatment option.
Read more →SMMTIvonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
Summit Therapeutics' partner, Akeso Inc., has reported updated data from the Phase III HARMONi-2 trial, which demonstrates that ivonescimab monotherapy provides significant and clinically meaningful benefits compared to pembrolizumab in patients with PD-L1-positive advanced NSCLC. This data will be presented at the IASLC 2026 World Conference on Lung Cancer in Seoul.
Read more →SMMT▲ +17.3%on this news
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
Summit Therapeutics' partner Akeso has reported positive results from the Phase III HARMONi-2 study. The trial demonstrated that ivonescimab monotherapy significantly improves overall survival compared to pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer. This finding could impact treatment strategies in this patient demographic.
Read more →SMMT▲ +6.5%on this news
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
Summit Therapeutics' partner, Akeso Inc., reported positive topline results from the Phase III HARMONi-GI1 study. The trial evaluated ivonescimab combined with chemotherapy against durvalumab plus chemotherapy for advanced biliary tract cancer. The results indicate a statistically significant overall survival benefit for the ivonescimab regimen in a single-region study conducted in China.
Read more →SMMTIvonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
Summit Therapeutics Inc. has published primary analysis results from the global Phase III HARMONi trial in The Lancet Oncology. The study found that ivonescimab, when combined with platinum-doublet chemotherapy, significantly improves progression-free survival compared to the placebo. This finding highlights the potential of ivonescimab in treating patients with EGFR mutations.
Read more →SMMTIvonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Summit Therapeutics announced that its partner Akeso has received marketing authorization from the NMPA in China for ivonescimab. This bispecific antibody is approved for use in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer. This approval marks a significant milestone for the treatment of this patient population.
Read more →SMMTSummit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
Summit Therapeutics has announced the launch of the Phase II/III HARMONi-GU1 trial, expanding its clinical development program for ivonescimab in bladder cancer. This global study aims to evaluate the efficacy of ivonescimab in combination with an antibody-drug conjugate. The trial represents a significant step in the treatment of urothelial carcinoma.
Read more →SMMT▼ -8.8%on this news
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
Summit Therapeutics Inc. reported its financial results for Q2 and the first half of 2026, highlighting significant operational advancements. The company emphasized the clinical progress of ivonescimab, particularly following promising results from the HARMONi-6 Phase III study. These developments are expected to strengthen their position in the market.
Read more →SMMTIvonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Summit Therapeutics Inc. has reported updated overall survival results from the Phase III HARMONi trial, demonstrating that ivonescimab combined with platinum-doublet chemotherapy continues to show a favorable trend. The results indicate consistent efficacy and safety across both Asian and western patient populations compared to chemotherapy alone.
Read more →SMMT▼ -8.7%on this news
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
Summit Therapeutics Inc. will host a conference call on July 23, 2026, to discuss its second quarter financial results and operational updates. The call is set for 4:30 p.m. EDT and will be accessible via the company's website. This event highlights the company's commitment to investor relations and transparency.
Read more →SMMTSummit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
Summit Therapeutics has entered into an agreement to sell its Phase III asset, ridinilazole, to Biossil, Inc. This precision antibiotic was previously evaluated in the Phase III Ri-CoDIFy study. The transaction allows Summit to concentrate on other initiatives while Biossil aims to advance the drug for life-threatening conditions.
Read more →SMMTSummit Therapeutics Announces Proposed Public Offering of Common Stock
Summit Therapeutics has announced a proposed public offering of common stock. However, the article does not provide specific details about the offering, including the number of shares or pricing. The lack of information raises concerns about transparency and investor interest.
Read more →SMMT▼ -10.4%on this news
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
The article discusses the HARMONi-6 study conducted by Akeso in China, which compares Ivonescimab with chemotherapy against Tislelizumab plus chemotherapy for first-line treatment of patients with squamous non-small cell lung cancer (NSCLC). However, the article lacks specific details regarding the study's findings or implications.
Read more →SMMT▼ -10.4%on this newsshared move
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
The article discusses the presentation of Phase II data for Ivonescimab in first-line metastatic colorectal cancer at ASCO 2026. However, specific details about the data or outcomes are not provided in the text. The overall sentiment appears neutral due to the lack of detailed information.
Read more →SMMTSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
Summit Therapeutics reported its financial results and operational updates for Q1 2026, highlighting progress in clinical trials for ivonescimab, a bispecific antibody. The FDA has accepted the Biologics License Application for ivonescimab, with a PDUFA goal date set for November 14, 2026. Despite a significant increase in operating expenses and net loss, the company maintains a strong cash position.
Read more →SMMTMultiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
Summit Therapeutics announced that updated data on ivonescimab will be showcased at the ELCC 2026. The presentations will include findings from the global HARMONi Phase III study, demonstrating improved intracranial progression-free survival in patients with EGFR-mutated NSCLC. The data indicates potential benefits of ivonescimab when combined with chemotherapy, with no new safety concerns reported.
Read more →About Summit Therapeutics Inc.
Headquarters601 BRICKELL KEY DRIVE, MIAMI, FL, 33131
BIOPHARMAWATCH ELITE PLUS
Trade the next SMMT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime